Mr. Bouchard, I can get you copies of documents issued by the Access to Medicine Foundation, which conducted an assessment of global trends. To answer your question, we began using our generic medicines through more voluntary and more creative measures. We could provide you with a long list of voluntary collaboration examples.
I think that we are beginning to see that in the case of our generic products and of patients who need them, there are quicker, more flexible and more effective measures than those included in the legislation. I think that we all want to do the same thing, but we must ask ourselves how we can save lives. Everyone is seeking ways to function as effectively as possible on a global scale. I would like to reiterate that, often, by collaborating with the makers of innovative and generic products, we find solutions that are independent from this legislation.